乳腺癌|乳腺癌 Her2 低表达亚型，会成为新的生物学亚型吗？( 二 ) 乳腺癌|her2|生物学|癌症

题图来源：站酷海洛PLUS
参考文献：
[1]. International Agency for Research on Cancer 2020, World Health Organization (https://gco.iarc.fr/today/home);
[2]. Slamon DJ, Leyland-Jones B,et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001 Mar 15;344(11):783-92.
[3]. Smith IE. Efficacy and safety of Herceptin in women with metastatic breast cancer: results from pivotal clinical studies. Anticancer Drugs. 2001 Dec;12 Suppl 4:S3-10.
[4]. Slamon DJ, Godolphin W, et al, Press MF: Studies of the HER2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707–712.
[5]. Gilcrease MZ, Woodward WA, Nicolas MM, et al: Even low-level HER2 expression may be associated with worse outcome in node-positive breast cancer. Am J Surg Pathol 33:759-767, 2009
[6]. Birner P, Oberhuber G, Stani J, et al: Evaluation of the United States Food and Drug Administration-approved scoring and test system of HER-2 protein expression in breast cancer. Clin Cancer Res 7:1669-1675, 2001
[7]. Camp RL, Dolled-Filhart M, King BL, et al: Quantitative analysis of breast cancer tissue microarrays shows that both high and normal levels of HER2 expression are associated with poor outcome. Cancer Res 63:1445-1448, 2003
[8]. Fehrenbacher L, Cecchini R, Geyer C, et al: Abstract GS1-02: NSABP B-47 (NRG oncology): Phase III randomized trial comparing adjuvant chemotherapy with adriamycin (A) and cyclophosphamide (C)weekly paclitaxel (WP), or docetaxel (T) and C with or without a year of trastuzumab (H) in women with node positive or high-risk node-negative invasive breast cancer (IBC) expressing HER2 staining intensity of IHC 1+ or 2+ with negative FISH (HER2-Low IBC). Cancer Res 78:GS1-02-GS1-02, 2018 (4 suppl)
[9]. Di Leo A, Gomez HL, et al. Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J Clin Oncol. 2008 Dec 1;26(34):5544-52.
[10]. Gianni L, Lladó A, et al. Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2010 Mar 1;28(7):1131-7.
[11]. Eiger D, Agostinetto E, et al. The Exciting New Field of HER2-Low Breast Cancer Treatment. Cancers (Basel). 2021 Mar 1;13(5):1015.
[12]. Tarantino P, Hamilton E, et al. HER2-Low Breast Cancer: Pathological and Clinical Landscape. J Clin Oncol. 2020 Jun 10;38(17):1951-1962.
[13]. Denkert C, Seither F, et al. Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials. Lancet Oncol. 2021 Aug;22(8):1151-1161.
【乳腺癌|乳腺癌 Her2 低表达亚型，会成为新的生物学亚型吗？】[14]. Guidelines of chinese society of clinical onclogy breast cancer. Beijing: People's Medical Publishing House, 2021.